Lisata Therapeutics to be Acquired by Kuva Labs for $4 Cash Per Share

 Stockholders to also receive two contingent value rights valued at $1 per share, each entitled to be received upon the achievement of certain milestones

Offer represents an approximate 85% premium over the most recent closing price of Lisata stock

https://www.globenewswire.com/news-release/2026/01/21/3222654/18623/en/Lisata-Therapeutics-Enters-Into-Term-Sheet-to-be-Acquired-by-Kuva-Labs-for-4-00-Per-Share-in-an-All-Cash-Tender-Offer.html